Menu
Recruiting NCT06066918

Prophylactic Pregabalin Treatment Following Spinal Cord Injury

No phase Interventional Spinal Cord Injuries Spinal Cord Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Pregabalin 75mg.
Who it may be relevant to
Registry conditions: Spinal Cord Injuries, Spinal Cord Diseases. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Israel
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain

Overview

Patients arriving to rehabilitation up to 3 months following SCI will be given (study group) or not (control group) Lyrica (75X2). They will be followed for central pain development.

Detailed description

Patients arriving to rehabilitation up to 3 months following SCI will be recruited, if they have not yet developed central pain. Two thirds (the study group) will be treated with Lyrica (Pregabalin75X2) for 3 months. One third (the control group) will not receive preventative treatment. Participants will be followed for central pain development.

Interventions

  • Drug Pregabalin 75mg
    Pregabalin 75 mg twice a day

Primary outcome measures

  • Central pain [Time frame: 1 year]
  • McGill Pain Questionnaire [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • Up to 3 months following traumatic or non-traumatic SCL
  • Ability to give informed consent and cooperate

Exclusion criteria

  • Pregnancy
  • Neurological or other medical conditions that may interfere with sensation
  • Neuropathic-like pain before recruitment (described as painful sensation of electric current, burning, numbness, tingling, pricking, or squeezing)
  • Being treated with Pregabalin
  • Blood creatinine levels >1.2 or creatinine clearance <60
  • Sensitivity to lactose

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

Israel · 1 center
  • Loewenstein Rehabilitation Hospital — Raanana

Identifiers

NCT: NCT06066918 · 0012-19-LOE

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗